Generalized Pustular Psoriasis Market

1
(No Transcript)
2
Generalized Pustular Psoriasis (GPP)
01
Generalized Pustular Psoriasis (GPP) is a severe
form of skin disorder called psoriasis. GPP is
caused by abnormal inflammation.
02
Mutations occur in several genes, including
IL36RN and CARD14. They increase the risk of
developing Generalized Pustular Psoriasis.
IL-36Ra protein produced from the IL36RN gene
blocks the activity of specific proteins for not
promoting skin inflammation. IL36RN gene
mutations involved in GPP reduce the amount of
IL-36Ra protein in the skin.
03
04
Generalized Pustular Psoriasis (GPP) is more
common in females as compared to males worldwide.

• DelveInsight 2019 All rights reserved

3
GPP Epidemiology
Generalized Pustular Psoriasis (GPP) is a rare
disease and is the rarest form of psoriasis.
In patients with a family history of psoriasis
or homozygous mutation of IL36RN, onset age is
earlier.
GPP accounts for 0.6 to 7 of all cases of
psoriasis and age of onset is between 3 and 16
years.
GPP prevalence was 1.76 per million in France
whereas Japan prevalence was 7.46 per million.
GPP prevalence affects 2 per million in Europe
and occurs in 0.6 per million in Japan.

• DelveInsight 2019 All rights reserved

4
GPP Market Outlook
GPP market scenario reveals lack of targeted GPP
therapies for cure but there are some symptomatic
GPP treatments which are being given to the
patients. Disease severity and extent of skin
involvement may be helpful to determine GPP
treatment.
Extensive research and development activities of
companies to develop GPP therapies that will
create a positive impact GPP market during the
forecast period (2019-2028).
Current research is focused on the development of
biologic therapies targeting IL-1, IL-12/23p40,
and IL-17A receptors. Anakinra is a biologic
therapy and is an IL-1 receptor antagonist for
treating GPP, and gevokizumab is an IL-1ß
inhibitor for treating GPP patients.
Drugs in the clinical trials are expected to
propel the growth of GPP drugs market in the
upcoming years.

• DelveInsight 2019 All rights reserved

5
GPP Emerging Drugs and Companies
Drug ANB019 by AnaptysBio
GPP market dynamics is anticipated to change in
the coming years owing to the rising awareness of
the disease. This provides an opportunity for
other companies to enter the market like
AnaptysBio and Boehringer Ingelheim that are
involved in developing GPP therapies.
Drug BI655130 by Boehringer Ingelheim

• DelveInsight 2019 All rights reserved

6
Complete Information
For complete information on
Generalized Pustular Psoriasis Market Insights,
Epidemiology Market Forecast-2028 please
click the link below
CLICK HERE
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2019 All rights reserved

• DelveInsight 2019 All rights reserved

7
About DelveInsight
1
2
3

• DelveInsight 2019 All rights reserved

8
Services by DelveInsight
PharmDelve
Forecasting
Opportunity Assessment
Consulting
Report Store
Market Intelligence
Competitive Analysis
Pipeline

• DelveInsight 2019 All rights reserved

9
Contact Us
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

• DelveInsight 2019 All rights reserved

10
Contact Us
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

• DelveInsight 2019 All rights reserved